Affiliation:
1. Krasnoyarsk State Medical University named after Prof. V.F. Voyno-Yasenetsky;
Krasnoyarsk Regional Clinical Oncology Center named after A.I. Kryzhanovsky
2. The Center of Nuclear Medicine of the Siberian Research Clinical Centre, FMBA of Russia
3. Krasnoyarsk State Medical University named after Prof. V.F. Voyno-Yasenetsky
4. Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Science;
National Research Tomsk Polytechnic University
Abstract
The purpose is to present a modern data on the possibilities of positron emission computed tomography combined with computed tomography (PET/CT) in the diagnosis, staging and monitoring of prostate cancer (PC).Material and Methods. A search and analysis of the largest domestic and English-language databases (Elibrary, PubMed, Elsevier, etc.) on this problem was carried out. 37 sources were found devoted to studying the results of clinical trials of the diagnostic capabilities of PET/CT with various radiopharmaceuticals.Results. The presented data on the possibilities of PET/CT with various radiopharmaceuticals in the diagnosis of primary prostate cancer, imaging of lymphogenous and distant metastases, as well as in assessing the effectiveness of treatment.Conclusion. This review of the literature showed that the use of PET/CT in prostate cancer largely depends on the chosen radiopharmaceutical. Moreover, it is PET/CT with PSMA-based radiopharmaceuticals that is the most promising method for examining patients with prostate cancer and can be recommended as an additional study in cases where other methods of radiation diagnostics do not give an unambiguous answer. The development of new and improving the already used radiopharmaceuticals, which will increase the sensitivity, specificity and accuracy of the diagnosis, staging, monitoring and prognosis of treatment of prostate cancer, remains relevant.
Publisher
Tomsk Cancer Research Institute